JP2013526545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526545A5 JP2013526545A5 JP2013510313A JP2013510313A JP2013526545A5 JP 2013526545 A5 JP2013526545 A5 JP 2013526545A5 JP 2013510313 A JP2013510313 A JP 2013510313A JP 2013510313 A JP2013510313 A JP 2013510313A JP 2013526545 A5 JP2013526545 A5 JP 2013526545A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- use according
- days
- injection
- methotrexate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33454610P | 2010-05-13 | 2010-05-13 | |
| US61/334,546 | 2010-05-13 | ||
| US12/914,944 | 2010-10-28 | ||
| US12/914,944 US9770414B2 (en) | 2010-05-13 | 2010-10-28 | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| PCT/US2011/036328 WO2011143484A1 (en) | 2010-05-13 | 2011-05-12 | A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015188829A Division JP6263508B2 (ja) | 2010-05-13 | 2015-09-25 | 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013526545A JP2013526545A (ja) | 2013-06-24 |
| JP2013526545A5 true JP2013526545A5 (cg-RX-API-DMAC10.html) | 2014-06-26 |
| JP5980775B2 JP5980775B2 (ja) | 2016-08-31 |
Family
ID=44911988
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510313A Active JP5980775B2 (ja) | 2010-05-13 | 2011-05-12 | 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 |
| JP2015188829A Active JP6263508B2 (ja) | 2010-05-13 | 2015-09-25 | 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 |
| JP2017013045A Withdrawn JP2017071652A (ja) | 2010-05-13 | 2017-01-27 | 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015188829A Active JP6263508B2 (ja) | 2010-05-13 | 2015-09-25 | 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 |
| JP2017013045A Withdrawn JP2017071652A (ja) | 2010-05-13 | 2017-01-27 | 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9770414B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2568962B1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP5980775B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN103002877B (cg-RX-API-DMAC10.html) |
| IL (1) | IL222683B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011143484A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104427977B (zh) | 2012-05-10 | 2018-02-02 | 佩因拉佛姆有限公司 | 局部麻醉剂的储库制剂及其制备方法 |
| BR112015000174A2 (pt) | 2012-07-05 | 2017-06-27 | Taiwan Liposome Co Ltd | método para o tratamento da artrite |
| WO2015147018A1 (ja) * | 2014-03-28 | 2015-10-01 | テルモ株式会社 | 炎症性自己免疫疾患治療用の注射用水性製剤 |
| WO2015183213A1 (en) * | 2014-05-28 | 2015-12-03 | Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid |
| CA2991921C (en) | 2014-07-30 | 2023-08-08 | Massachusetts Eye And Ear Infirmary | Methotrexate for proliferative vitreoretinopathy |
| JP5774190B1 (ja) * | 2014-12-12 | 2015-09-09 | ジーンメディカル株式会社 | 皮下注射用剤及び皮下注射用剤を含有する注射器の製造方法 |
| US10918766B2 (en) | 2014-12-12 | 2021-02-16 | Motejo Ltd. | Agent for hypodermic injection |
| WO2017004136A1 (en) | 2015-06-30 | 2017-01-05 | Tela Bio, Inc. | Corner-lock stitch patterns |
| US10426587B2 (en) | 2015-07-21 | 2019-10-01 | Tela Bio, Inc. | Compliance control stitching in substrate materials |
| EP3383482B1 (en) | 2015-11-24 | 2023-01-04 | Massachusetts Institute of Technology | Systems for preventing, mitigating, and/or treating dementia |
| US9820843B2 (en) | 2016-04-26 | 2017-11-21 | Tela Bio, Inc. | Hernia repair grafts having anti-adhesion barriers |
| KR102584446B1 (ko) | 2016-08-12 | 2023-10-04 | 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. | 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도 |
| WO2018031979A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| CA3044440A1 (en) | 2016-11-17 | 2018-05-24 | Cognito Therapeutics, Inc. | Methods and systems for neural stimulation via visual stimulation |
| KR102069670B1 (ko) * | 2017-03-02 | 2020-01-23 | 단디바이오사이언스 주식회사 | 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
| ES3058718T3 (en) | 2017-10-10 | 2026-03-12 | Massachusetts Inst Technology | Systems for preventing, mitigating, and/or treating dementia |
| US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
| CA3082643A1 (en) | 2017-11-14 | 2019-05-23 | The Schepens Eye Research Institute, Inc. | Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
| CN115475142A (zh) * | 2017-11-20 | 2022-12-16 | 平顶山学院 | 一种口服甲氨蝶呤脂质体及其制备方法 |
| CA3090391A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| JP7491573B2 (ja) * | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| US12246018B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| CA3090384A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| WO2019157133A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| EP3749317A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| WO2019157148A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| WO2019157146A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| JP7514533B2 (ja) * | 2018-02-07 | 2024-07-11 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化テトラヒドロ葉酸およびその使用 |
| CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| US12290518B2 (en) | 2018-02-14 | 2025-05-06 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| JP7442822B2 (ja) * | 2018-02-14 | 2024-03-05 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | γポリグルタミン酸化テトラヒドロ葉酸およびその使用 |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| US12048767B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| EP3761963B1 (en) | 2018-03-09 | 2025-01-22 | Tela Bio, Inc. | Surgical repair graft |
| EP3934575B1 (en) | 2019-03-08 | 2025-05-07 | Tela Bio, Inc. | Textured medical textiles |
| CN110269939A (zh) * | 2019-03-12 | 2019-09-24 | 武汉愔紫生物科技有限公司 | 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法 |
| US12678440B2 (en) | 2020-02-26 | 2026-07-14 | Case Western Reserve University | Compositions and methods for treating misfolded protein ocular disorders |
| WO2021216957A1 (en) * | 2020-04-23 | 2021-10-28 | Massachusetts Institute Of Technology | Systems, devices, and methods for gamma entrainment using sensory stimuli to alleviate cognitive deficits and/or neuroinflammation induced by chemotherapy agents |
| CN114249731B (zh) * | 2020-09-24 | 2023-09-29 | 南京海润医药有限公司 | 一种甲氨蝶呤中间体的精制方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4565696A (en) * | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
| GB8704171D0 (en) * | 1987-02-23 | 1987-04-01 | Clayton Found Res | Multivesicular liposomes |
| US5723147A (en) * | 1987-02-23 | 1998-03-03 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
| US5807572A (en) * | 1988-02-18 | 1998-09-15 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| ZA911974B (en) * | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| HUT75162A (en) | 1993-11-16 | 1997-04-28 | Depotech Corp | Vesicles with controlled release of actives |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| US6306432B1 (en) * | 1997-09-08 | 2001-10-23 | Chiron Corporation | High and low load formulations of IGF-I in multivesicular liposomes |
| WO1999022601A1 (en) * | 1997-11-05 | 1999-05-14 | Biozone Laboratories, Inc. | Enhanced infant formula containing liposome encapsulated nutrients and agents |
| AU752802C (en) * | 1997-11-14 | 2006-04-13 | Pacira Pharmaceuticals, Inc. | Production of multivesicular liposomes |
| IL158532A0 (en) * | 2001-05-02 | 2004-05-12 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US8043602B2 (en) * | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US20040176381A1 (en) * | 2003-03-06 | 2004-09-09 | Walsh Michael J. | Methotrexate compliance packaging |
| US6921667B2 (en) * | 2003-03-07 | 2005-07-26 | Prometheus Laboratories, Inc. | Methods for direct detection of individual methotrexate metabolites |
| CN101905023B (zh) * | 2004-07-16 | 2012-07-11 | 杏林制药株式会社 | 有效的医药使用方法及与副作用发生的防御相关的方法 |
| JP2008512490A (ja) | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス，インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
| US20060116334A1 (en) * | 2004-12-01 | 2006-06-01 | Curt Hendrix | Folate based composition for treatment of the cardiovascular system |
| WO2006122414A1 (en) | 2005-05-17 | 2006-11-23 | Matregen Corp. | Depot for sustained and controlled delivery of methotrexate |
| JP5175723B2 (ja) * | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| EP2040674B1 (en) * | 2006-05-18 | 2010-07-07 | MediGene AG | Cationic liposomal preparations for the treatment of rheumatoid arthritis |
| DE102006033837A1 (de) | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
| WO2008030818A2 (en) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Novel liposome compositions |
| US20080075807A1 (en) * | 2006-09-22 | 2008-03-27 | Baldwin Cheryl J | Methods Of Fortifying Foods With Vitamin D And Food Products Thereof |
| GB2443738A (en) | 2006-11-09 | 2008-05-14 | Proprius Pharmaceuticals Inc | A sustained release methotrexate composition and methods of use thereof |
| WO2009029543A1 (en) | 2007-08-24 | 2009-03-05 | Aegis Therapeutics, Llc | Controlled release formulations |
| MX2010007393A (es) * | 2008-01-03 | 2010-11-09 | Abbott Biotech Ltd | Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis. |
-
2010
- 2010-10-28 US US12/914,944 patent/US9770414B2/en active Active
-
2011
- 2011-05-12 EP EP11781306.3A patent/EP2568962B1/en active Active
- 2011-05-12 JP JP2013510313A patent/JP5980775B2/ja active Active
- 2011-05-12 CN CN201180023882.8A patent/CN103002877B/zh active Active
- 2011-05-12 WO PCT/US2011/036328 patent/WO2011143484A1/en not_active Ceased
-
2012
- 2012-10-25 IL IL222683A patent/IL222683B/en active IP Right Grant
-
2013
- 2013-03-05 US US13/786,368 patent/US20130183371A1/en not_active Abandoned
- 2013-03-05 US US13/786,323 patent/US10028911B2/en active Active
-
2015
- 2015-09-25 JP JP2015188829A patent/JP6263508B2/ja active Active
-
2017
- 2017-01-27 JP JP2017013045A patent/JP2017071652A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9770414B2 (en) | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent | |
| EP3964200A1 (en) | Compositions and methods for delivery of therapeutic agents | |
| Van Hoogevest et al. | The use of phospholipids to make pharmaceutical form line extensions | |
| JP2015515992A5 (cg-RX-API-DMAC10.html) | ||
| FI3821887T3 (fi) | Mitoksantroni liposomin käyttö ei-hodgkinin lymfooman hoitoon | |
| RU2015103538A (ru) | Способы лечения артрита | |
| JP2017515913A5 (cg-RX-API-DMAC10.html) | ||
| CL2013003621A1 (es) | Composición farmacéutica inhalable que comprende una dispersión de partículas liposomales que contienen un agente bioactivo hidrófobo, tal como coq10, un fosfolípido, y un vehículo de dispersión acuosa, apta para aerosolización continua; método de preparación; método de administración; uso para tratar enfermedades del pulmón. | |
| JP2017536092A5 (cg-RX-API-DMAC10.html) | ||
| JP2017517533A5 (cg-RX-API-DMAC10.html) | ||
| TWI660749B (zh) | 設計脂質體水相和非水相部分的組成來控制藥物的釋放趨勢 | |
| JP2016513651A5 (cg-RX-API-DMAC10.html) | ||
| JP2015502400A5 (cg-RX-API-DMAC10.html) | ||
| BR112015022476A2 (pt) | composições de oxaliplatina de lipossoma para terapia de câncer | |
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| TR201818978T4 (tr) | İnsanlardaki İnflamatuvar Rahatsızlıkların Tedavisine Yönelik Lipozomal Kortikosteroidler | |
| JP2008540364A (ja) | パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法 | |
| JP2017516829A5 (cg-RX-API-DMAC10.html) | ||
| NZ700472A (en) | Use of vesicular formations in the manufacture of a medicament for treating rosacea | |
| JP2022088622A (ja) | がん療法のためのメトロノミック経口ゲムシタビン | |
| JP2015500840A5 (cg-RX-API-DMAC10.html) | ||
| EA027506B1 (ru) | Способ лечения рака молочной железы | |
| HK40070194A (en) | Compositions and methods for delivery of therapeutic agents | |
| US20240358639A1 (en) | Nanoparticles for cancer treatment | |
| RU2021102771A (ru) | Применение липосомы митоксантрона для лечения неходжкинской лимфомы |